Latest Commentary

Pfizer aims ambitious PCSK9 program at payers, skeptical regulators

Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs in the industry for RN-316. This week, the pharma giant spelled out plans for a massive cardiovascular outcomes trial to prove to regulators and payers alike that the drug not only works as advertised, but delivers real value to patients.

Top 10 rheumatoid arthritis drugs 2013

Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...

Fierce welcomes newest publication: FierceDiagnostics

Three years ago, the Fierce Life Sciences team launched FierceMedicalDevices to provide more coverage in the medtech space. Now we're expanding yet again with the launch of our newest publication, FierceDiagnostics.

10 Top-selling Diabetes Drugs - 2012

The prevalence of diabetes is growing globally, and with that the size of the diabetes drug market. But the market has gotten increasingly competitive and increasingly complex. All of the top 10 best-selling drugs in the diabetes category are blockbusters, according to EvaluatePharma. So who makes them? Check out the report >>

What we talk about when we talk (on LinkedIn) about pharma

FiercePharma has launched a LinkedIn group. We'd like you to join. Share the news of the day with us. Chat about trends and problems. Suggest story topics, nominate your companies and colleagues for special reports. Tell us your office jokes, even. War stories are great, too. We'll also be soliciting your opinions about the latest issues. Join the group here.

Join the FiercePharma LinkedIn group

I don't need to tell you the importance of connections and networking. Every day deals are made and agreements are reached with the help of networks and connections. At FiercePharma, we pride...

2013 looks great from top execs' perspective

Many of the executives prowling the corridors and holding confabs at the J.P. Morgan Healthcare Conference this week viewed their own companies as well-positioned and saw a lot to like about what will happen this year.

How will pharma fare in 2013? It's complicated

As in years past, we're using our last newsletter issue of the year to dissect the 5 trends we expect to prove important, fascinating and perhaps both, over the next 12 months.

Which FiercePharma news attracts the most readers online?

As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>

Giving thanks for turkey basters, and national holidays

You know you're in for a job when carrying the Thanksgiving turkey to the car counts as weight training. The 27-pound bird now resting in FiercePharma's pantry will need plenty of babysitting...